According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Dengue comes with fever, body pain, and a whole lot of confusion, especially when it comes to treatment. The moment someone ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

The European regulator’s anniversary year featured first-in-class therapies, rare-disease advances, safety warnings, and new ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports ...